NASDAQ:EOLS

Evolus Stock Insider Trading

Healthcare > Drug Manufacturers - Specialty & Generic

Buy EOLS

*Your capital is at risk

$6.17

-0.350 (-5.37%)

At Close: Jun 02, 2026

Evolus Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -25.96. In total, the insiders bought 4.65M and sold 822.79K EOLS shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-25.96
● Buy	4.65M shares
● Sell	822.79K shares
70% Buy Activity Strong Negative Correlation
Sell Signal Medium Confidence Mar 17, 2026 Analysis Breakdown: Supported by a negative Insider Power Score of -25.96. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 20, 2026 Sell	Common Stock S-Sale	Moatazedi David See Remarks	Officer	13 669 Value: $64.9K
Mar 20, 2026 Sell	Common Stock S-Sale	Avelar Rui See Remarks	Officer	3 119 Value: $14.8K
Mar 17, 2026 Sell	Common Stock S-Sale	Avelar Rui See Remarks	Officer	29 996 Value: $146.6K
Mar 17, 2026 Sell	Common Stock S-Sale	Moatazedi David See Remarks	Officer	116 720 Value: $570.6K
Mar 16, 2026 Buy	Performance Restricted Stock Units M-Exempt	Avelar Rui See Remarks	Officer	8 804 Value: $44.4K
Mar 16, 2026 Buy	Common Stock M-Exempt	Avelar Rui See Remarks	Officer	8 804 Value: $44.4K
Mar 16, 2026 Buy	Common Stock M-Exempt	Moatazedi David See Remarks	Officer	67 489 Value: $340.1K
Mar 16, 2026 Buy	Performance Restricted Stock Units M-Exempt	Moatazedi David See Remarks	Officer	67 489 Value: $340.1K
Feb 17, 2026 Buy	Common Stock A-Award	Gill David N Director	Director	45 559 Value: $200.0K
Feb 17, 2026 Buy	Performance Restricted Stock Units A-Award	Avelar Rui See Remarks	Officer	94 913 Value: $416.7K
Feb 17, 2026 Buy	Stock Option (Right to Buy) A-Award	Avelar Rui See Remarks	Officer	138 649 Value: $608.7K
Feb 17, 2026 Buy	Common Stock A-Award	Malik Vikram Director	Director	45 559 Value: $200.0K
Feb 17, 2026 Buy	Performance Restricted Stock Units A-Award	Moatazedi David See Remarks	Officer	626 424 Value: $2.75M
Feb 17, 2026 Buy	Stock Option (Right to Buy) A-Award	Mitchell Tatjana Chief Financial Officer	C-Suite Officer	177 471 Value: $779.1K
Feb 17, 2026 Buy	Common Stock A-Award	Moatazedi David See Remarks	Officer	313 212 Value: $1.38M
Feb 17, 2026 Buy	Common Stock A-Award	Mitchell Tatjana Chief Financial Officer	C-Suite Officer	121 489 Value: $533.3K
Feb 17, 2026 Buy	Common Stock A-Award	Stewart Brady Director	Director	45 559 Value: $200.0K
Feb 17, 2026 Buy	Common Stock A-Award	Parschauer Karah Herdman Director	Director	45 559 Value: $200.0K
Feb 17, 2026 Buy	Performance Restricted Stock Units A-Award	Mitchell Tatjana Chief Financial Officer	C-Suite Officer	121 489 Value: $533.3K
Feb 17, 2026 Buy	Common Stock A-Award	White Albert G Iii Director	Director	45 559 Value: $200.0K
Feb 17, 2026 Buy	Stock Option (Right to Buy) A-Award	Moatazedi David See Remarks	Officer	457 541 Value: $2.01M
Feb 17, 2026 Buy	Common Stock A-Award	Avelar Rui See Remarks	Officer	94 913 Value: $416.7K
Dec 22, 2025 Sell	Common Stock S-Sale	Avelar Rui See Remarks	Officer	2 261 Value: $16.2K
Dec 22, 2025 Sell	Common Stock S-Sale	Moatazedi David See Remarks	Officer	10 539 Value: $75.4K
Sep 08, 2025 Buy	Stock Option (Right to Buy) A-Award	Mitchell Tatjana Chief Financial Officer	C-Suite Officer	143 403 Value: $1.09M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT EVOLUS INC.

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California....

Read Full Profile Here